PFE
Pfizer Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$28.45
−1.25%Aug 6, 2026, 11:00 UTC
Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.
Source:Aug 5, 2026, 12:28 UTC
On August 5, 2026, Akeso announced that its overseas partner Summit Therapeutics will initiate a global Phase II/III clinical study (HARMONi-GU1/AK112-3008) combining ivonescimab with enfortumab vedotin for first-line treatment of locally advanced or metastatic urothelial carcinoma, with Akeso leading the China portion and Summit leading overseas portions.
Source:Aug 5, 2026, 12:15 UTC
Pfizer is seeking a new chief financial officer as Dave Denton is set to depart later this month.
Source:Aug 4, 2026, 14:38 UTC
Pfizer expanded its cost reduction plan to $7 billion and aims for an additional $2.5 billion in savings by 2029.
Jul 31, 2026, 19:00 UTC
Pfizer enforced a court judgment freezing funds owed to air traffic control agencies in Poland and Romania over unpaid COVID-19 vaccine doses, after both countries refused deliveries in 2022 and appealed the ruling.
Source:Jul 31, 2026, 05:23 UTC
Pfizer and Eisai will begin joint promotional activities in Japan for the migraine treatment NURTEC ODT 75mg from September, aiming to strengthen information provision for proper use.
Source:Jul 30, 2026, 10:46 UTC
Pfizer plans to initiate a pivotal study in 2026 evaluating Litfulo for the treatment of moderate alopecia areata.
Source:Jul 30, 2026, 10:45 UTC
Pfizer announced positive topline Phase 3 results for LITFULO in patients with nonsegmental vitiligo.
Source:Jul 27, 2026, 11:04 UTC
Pfizer announced that Amit Agarwal will resign as Chief Financial Officer, effective October 8, 2026.
Source:Jul 22, 2026, 20:30 UTC
The U.S. FDA accepted for Priority Review Pfizer's supplemental New Drug Application for TALZENNA in combination with XTANDI for the treatment of metastatic castration-sensitive prostate cancer.
Jul 16, 2026, 11:30 UTC
Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 10, 2026, 15:23 UTC
The U.S. FDA approved PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer.
Jul 9, 2026, 23:59 UTC
Pfizer and co-defendants reached a global settlement in principle with plaintiffs in the Depo-Provera multidistrict litigation on June 15, 2026.
Source:Jul 2, 2026, 17:51 UTC
Knoa Pharma appointed Michael Goettler as its CEO and president.
Source:Jul 2, 2026, 15:00 UTC
Pfizer obtained a Belgian court ruling leading to garnishment of funds destined for Romania via ROMATSA.
Jun 30, 2026, 21:52 UTC
Nike appointed Dave Denton, formerly CFO of Pfizer, as its new Finance Chief.
Source:Jun 29, 2026, 05:20 UTC
Pfizer's Ecnoglutide and Innovent Biologics' mazdutide injection passed a preliminary review by China's National Healthcare Security Administration for potential inclusion in the basic medical insurance drug catalogue.
Source:Jun 24, 2026, 19:52 UTC
Pfizer's board of directors declared a $0.43 per share quarterly cash dividend for the third quarter of 2026, payable on September 1, 2026, to shareholders of record on July 24, 2026.
Source:Jun 24, 2026, 18:10 UTC
The U.S. FDA approved Pfizer's IBRANCE regimen for maintenance treatment of HR+, HER2+ metastatic breast cancer.
Source:Jun 22, 2026, 21:36 UTC
Pfizer's experimental lung cancer drug sigvotatug vedotin failed to meet its endpoint in a clinical trial.
Source:Jun 19, 2026, 15:25 UTC
Pfizer's CFO Dave Denton announced his exit from the company.
Source:Jun 9, 2026, 15:56 UTC
Pfizer received FDA approval to expand the use of its hemophilia drug Hympavzi to additional patient groups, including children with inhibitors.
Source:Jun 8, 2026, 11:04 UTC
Pfizer reported positive mid-stage trial data for berobenatide, a GLP-1 obesity therapy with monthly dosing, and plans up to 10 Phase 3 trials for long-term obesity management and related conditions.
Source:Jun 8, 2026, 10:45 UTC
The U.S. FDA approved an expanded indication for Pfizer's HYMPAVZI to treat additional hemophilia A or B patient populations.
Source: